392 related articles for article (PubMed ID: 35150961)
1. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
[TBL] [Abstract][Full Text] [Related]
2. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of SARS-CoV-2 vaccines BBV152 (COVAXIN®) and ChAdOx1 nCoV-19 (COVISHIELD™) in seronegative and seropositive individuals in India: a multicentre, nonrandomised observational study.
Asokan MS; Joan RF; Babji S; Dayma G; Nadukkandy P; Subrahmanyam V; Pandey A; Malagi G; Arya P; Mahajan V; Bhavikatti J; Pawar K; Thorat A; Shah P; Goud RB; Roy B; Rajukutty S; Immanuel S; Agarwal D; Saha S; Shivaraj A; Panikulam P; Shome R; Gulzar SE; Sharma AU; Naik A; Talashi S; Belekar M; Yadav R; Khude P; V M; Shivalingaiah S; Deshmukh U; Bhise C; Joshi M; Inbaraj LR; Chandrasingh S; Ghose A; Jamora C; Karumbati AS; Sundaramurthy V; Johnson A; Ramesh N; Chetan N; Parthiban C; Ahmed A; Rakshit S; Adiga V; D'souza G; Rale V; George CE; John J; Kawade A; Chaturvedi A; Raghunathan A; Dias M; Bhosale A; Raghu P; Shashidhara LS; Vyakarnam A; Bal V; Kang G; Mayor S
Lancet Reg Health Southeast Asia; 2024 Mar; 22():100361. PubMed ID: 38482152
[TBL] [Abstract][Full Text] [Related]
4. Seroconversion Rate After SARS-CoV-2 Infection and Two Doses of Either ChAdOx1-nCOV COVISHIELD™ or BBV-152 COVAXIN™ Vaccination in Renal Allograft Recipients: An Experience of Two Public and Private Tertiary Care Center.
Prasad N; Bansal SB; Yadav B; Manhas N; Yadav D; Gautam S; Kushwaha R; Singh A; Bhadauria D; Yachha M; Behera MR; Kaul A
Front Immunol; 2022; 13():911738. PubMed ID: 35844596
[TBL] [Abstract][Full Text] [Related]
5. Single-dose of BBV-152 and AZD1222 increases antibodies against spike glycoprotein among healthcare workers recovered from SARS-CoV-2 infection.
Parai D; Choudhary HR; Dash GC; Sahoo SK; Pattnaik M; Rout UK; Nanda RR; Kanungo S; Kshatri JS; Pati S; Bhattacharya D
Travel Med Infect Dis; 2021; 44():102170. PubMed ID: 34653614
[No Abstract] [Full Text] [Related]
6. Evaluation of Humoral Immune Response after SARS-CoV-2 Vaccination Using Two Binding Antibody Assays and a Neutralizing Antibody Assay.
Nam M; Seo JD; Moon HW; Kim H; Hur M; Yun YM
Microbiol Spectr; 2021 Dec; 9(3):e0120221. PubMed ID: 34817223
[TBL] [Abstract][Full Text] [Related]
7. A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Iwata S; Pollard AJ; Tada Y; Omoto S; Shibata RY; Igarashi K; Hasegawa T; Ariyasu M; Sonoyama T
Sci Rep; 2024 Apr; 14(1):9830. PubMed ID: 38684712
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
9. Anti-SARS-CoV-2 Spike Protein RBD Antibody Levels After Receiving a Second Dose of ChAdOx1 nCov-19 (AZD1222) Vaccine in Healthcare Workers: Lack of Association With Age, Sex, Obesity, and Adverse Reactions.
Lee SW; Moon JY; Lee SK; Lee H; Moon S; Chung SJ; Yeo Y; Park TS; Park DW; Kim TH; Sohn JW; Yoon HJ; Kim SH
Front Immunol; 2021; 12():779212. PubMed ID: 34899739
[TBL] [Abstract][Full Text] [Related]
10. Persistence of Antibodies Against Spike Glycoprotein of SARS-CoV-2 in Healthcare Workers Post Double Dose of BBV-152 and AZD1222 Vaccines.
Choudhary HR; Parai D; Chandra Dash G; Kshatri JS; Mishra N; Choudhary PK; Pattnaik D; Panigrahi K; Behera S; Ranjan Sahoo N; Podder S; Mishra A; Raghav SK; Mishra SK; Pradhan SK; Sahoo SK; Pattnaik M; Rout UK; Nanda RR; Mondal N; Kanungo S; Palo SK; Bhattacharya D; Pati S
Front Med (Lausanne); 2021; 8():778129. PubMed ID: 35004746
[No Abstract] [Full Text] [Related]
11. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
12. A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala.
Varghese SM; Mateethra GC; George G; Chandran VS; John GM; Varghese LT; Mammen NK; Vinayak V
Indian J Med Res; 2022; 155(5&6):499-504. PubMed ID: 36348597
[TBL] [Abstract][Full Text] [Related]
13. Breakthrough SARS-CoV-2 infections among BBV-152 (COVAXIN®) and AZD1222 (COVISHIELD
Dash GC; Subhadra S; Turuk J; Parai D; Rath S; Sabat J; Rout UK; Kanungo S; Choudhary HR; Nanda RR; Pattnaik M; Pati S; Bhattacharya D
J Med Virol; 2022 Mar; 94(3):1201-1205. PubMed ID: 34622961
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of SARS-CoV-2 Humoral Response Following Vaccination with ChAdOx1 nCoV-19 (Covishield™) and/or Sinopharm, BBIBP-CorV (Vero cell™).
Kamar SB; Pandey H; Shahi R; Puri S; Yadav GK; Amgain K
J Nepal Health Res Counc; 2024 Mar; 21(3):523-529. PubMed ID: 38615227
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
16. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity and safety of homologous and heterologous booster vaccination of ChAdOx1 nCoV-19 (COVISHIELD™) and BBV152 (COVAXIN®): a non-inferiority phase 4, participant and observer-blinded, randomised study.
Rose W; Raju R; Babji S; George A; Madhavan R; Leander Xavier JV; David Chelladurai JS; Nikitha OS; Deborah AA; Vijayakumar S; Immanuel S; John J; Rupali P; Abhilash KPP; Mohan VR; Tallapaka KB; Samuel P; Kang G
Lancet Reg Health Southeast Asia; 2023 Jan; 12():100141. PubMed ID: 36712811
[TBL] [Abstract][Full Text] [Related]
18. Dynamicity and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study.
Parai D; Choudhary HR; Dash GC; Behera S; Mishra N; Pattnaik D; Raghav SK; Mishra SK; Sahoo SK; Swain A; Mohapatra I; Pattnaik M; Moharana A; Jena SR; Praharaj I; Subhadra S; Kanungo S; Bhattacharya D; Pati S
Front Microbiol; 2022; 13():942659. PubMed ID: 36016787
[TBL] [Abstract][Full Text] [Related]
19. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
